285 related articles for article (PubMed ID: 30115026)
41. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ
J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111
[TBL] [Abstract][Full Text] [Related]
42. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
[TBL] [Abstract][Full Text] [Related]
43. Usefulness of an RNA extraction-free test for the multiplexed detection of
Damiola F; Alberti L; Mansuet-Lupo A; Damotte D; Hofman V; Tixier L; Penault-Llorca F; Rouquette I; Vignaud JM; Cazes A; Forest F; Begueret H; Gibault L; Badoual C; Cayre A; Taranchon-Clermont E; Duc A; Mc Leer A; Lantuejoul S
Expert Rev Mol Diagn; 2023; 23(12):1283-1291. PubMed ID: 37906110
[TBL] [Abstract][Full Text] [Related]
44. Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
Sunami K; Furuta K; Tsuta K; Sasada S; Izumo T; Nakaoku T; Shimada Y; Saito M; Nokihara H; Watanabe S; Ohe Y; Kohno T
J Thorac Oncol; 2016 Feb; 11(2):203-12. PubMed ID: 26845116
[TBL] [Abstract][Full Text] [Related]
45. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
46. CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation RNA Sequencing.
Stockley TL; Lo B; Box A; Corredor AG; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Greer W; Hawkins C; Huang WY; Izevbaye I; Lépine G; Martins Filho SN; Papadakis AI; Park PC; Riviere JB; Sheffield BS; Spatz A; Spriggs E; Tran-Thanh D; Yip S; Zhang T; Torlakovic E; Tsao MS
J Mol Diagn; 2023 Mar; 25(3):168-174. PubMed ID: 36586421
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
Davies KD; Le AT; Sheren J; Nijmeh H; Gowan K; Jones KL; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2018 Oct; 13(10):1474-1482. PubMed ID: 29935306
[TBL] [Abstract][Full Text] [Related]
48. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
49. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
50. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
51. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
52. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
Lung J; Lin YC; Hung MS; Jiang YY; Lee KD; Lin PY; Tsai YH
Lung Cancer; 2016 Apr; 94():114-20. PubMed ID: 26973216
[TBL] [Abstract][Full Text] [Related]
53. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
54. The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.
Cerrato A; Visconti R; Celetti A
Mol Cancer; 2018 Feb; 17(1):46. PubMed ID: 29455670
[TBL] [Abstract][Full Text] [Related]
55. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
56. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
57. Feasibility and clinical utility of a pan-solid tumor targeted RNA fusion panel: A single center experience.
Hindi I; Shen G; Tan Q; Cotzia P; Snuderl M; Feng X; Jour G
Exp Mol Pathol; 2020 Jun; 114():104403. PubMed ID: 32061944
[TBL] [Abstract][Full Text] [Related]
58. Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern.
Kao YC; Suurmeijer AJH; Argani P; Dickson BC; Zhang L; Sung YS; Agaram NP; Fletcher CDM; Antonescu CR
Genes Chromosomes Cancer; 2020 Oct; 59(10):575-583. PubMed ID: 32506523
[TBL] [Abstract][Full Text] [Related]
59. Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.
Yamamoto G; Kikuchi M; Kobayashi S; Arai Y; Fujiyoshi K; Wakatsuki T; Kakuta M; Yamane Y; Iijima Y; Mizutani H; Nakajima Y; Sudo J; Kinoshita H; Kurimoto F; Akiyama H; Uramoto H; Sakai H; Akagi Y; Akagi K
Int J Oncol; 2017 May; 50(5):1579-1589. PubMed ID: 28350094
[TBL] [Abstract][Full Text] [Related]
60. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay.
Gruber K; Horn H; Kalla J; Fritz P; Rosenwald A; Kohlhäufl M; Friedel G; Schwab M; Ott G; Kalla C
J Thorac Oncol; 2014 Mar; 9(3):307-15. PubMed ID: 24495999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
